PuSH - Publikationsserver des Helmholtz Zentrums München

Loureiro, H. ; Kolben, T.M.* ; Kiermaier, A.* ; Rüttinger, D.* ; Ahmidi, N. ; Becker, T.* ; Bauer-Mehren, A.*

Correlation between early trends of a prognostic biomarker and overall survival in non-small-cell lung cancer clinical trials.

JCO Clin. Can. Inform. 7:e2300062 (2023)
Verlagsversion DOI PMC
Open Access Gold (Paid Option)
Creative Commons Lizenzvertrag
PURPOSE: Overall survival (OS) is the primary end point in phase III oncology trials. Given low success rates, surrogate end points, such as progression-free survival or objective response rate, are used in early go/no-go decision making. Here, we investigate whether early trends of OS prognostic biomarkers, such as the ROPRO and DeepROPRO, can also be used for this purpose. METHODS: Using real-world data, we emulated a series of 12 advanced non-small-cell lung cancer (aNSCLC) clinical trials, originally conducted by six different sponsors and evaluated four different mechanisms, in a total of 19,920 individuals. We evaluated early trends (until 6 months) of the OS biomarker alongside early OS within the joint model (JM) framework. Study-level estimates of early OS and ROPRO trends were correlated against the actual final OS hazard ratios (HRs). RESULTS: We observed a strong correlation between the JM estimates and final OS HR at 3 months (adjusted R2 = 0.88) and at 6 months (adjusted R2 = 0.85). In the leave-one-out analysis, there was a low overall prediction error of the OS HR at both 3 months (root-mean-square error [RMSE] = 0.11) and 6 months (RMSE = 0.12). In addition, at 3 months, the absolute prediction error of the OS HR was lower than 0.05 for three trials. CONCLUSION: We describe a pipeline to predict trial OS HRs using emulated aNSCLC studies and their early OS and OS biomarker trends. The method has the potential to accelerate and improve decision making in drug development.
Altmetric
Weitere Metriken?
[➜Einloggen]
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Korrespondenzautor
ISSN (print) / ISBN 2473-4276
e-ISSN 2473-4276
Zeitschrift JCO Clinical Cancer Informatics
Quellenangaben Band: 7, Heft: , Seiten: , Artikelnummer: e2300062 Supplement: ,
Verlag American Society of Clinical Oncology
Verlagsort Alexandria
Nichtpatentliteratur Publikationen
Institut(e) Institute of Computational Biology (ICB)